SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (14462)12/3/2004 9:43:36 AM
From: rkrw  Read Replies (1) | Respond to of 52153
 
Just noticed the bpa ceo and vp regulatory affairs sold a bundle (30% of holdings) on Tuesday but didn't report until yesterday. Think they sensed the risk? :-)



To: rkrw who wrote (14462)12/3/2004 9:58:35 AM
From: Biomaven  Respond to of 52153
 
Is a pivotal trial that measures cancer risk for intrinsa (or libigel) practical? Would a (theoretical) increased cancer risk for micro testosterone doses emerge in a one year study no matter how many patients?

I'd say no. You'd need 10 years, several thousand patients.

But the question is whether the FDA would have the guts to make a call like that in the current environment.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News